GLP-1 receptor agonists have been used successfully and safely in type 2 diabetes mellitus (T2DM) and do not induce insulin desensitization after prolonged use, as they do not activate insulin receptors in normoglycemic subjects [16] and thus do not cause hypoglycemia. Here, INS is linked to type 2 diabetes mellitus.